作者
Anna S Lok, Leonard B Seeff, Timothy R Morgan, Adrian M Di Bisceglie, Richard K Sterling, Teresa M Curto, Gregory T Everson, Karen L Lindsay, William M Lee, Herbert L Bonkovsky, Jules L Dienstag, Marc G Ghany, Chihiro Morishima, Zachary D Goodman, HALT-C Trial Group
发表日期
2009/1/1
期刊
Gastroenterology
卷号
136
期号
1
页码范围
138-148
出版商
WB Saunders
简介
BACKGROUND & AIMS
Although the incidence of hepatocellular carcinoma (HCC) is increasing in the United States, data from large prospective studies are limited. We evaluated the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort for the incidence of HCC and associated risk factors.
METHODS
Hepatitis C virus-positive patients with bridging fibrosis or cirrhosis who did not respond to pegylated interferon (peginterferon) and ribavirin were randomized to groups that were given maintenance peginterferon for 3.5 years or no treatment. HCC incidence was determined by Kaplan-Meier analysis, and baseline factors associated with HCC were analyzed by Cox regression.
RESULTS
One thousand five patients (mean age, 50.2 years; 71% male; 72% white race) were studied; 59% had bridging fibrosis, and 41% had cirrhosis. During a median follow-up of 4.6 years (maximum, 6.7 years …
引用总数
学术搜索中的文章
AS Lok, LB Seeff, TR Morgan, AM Di Bisceglie… - Gastroenterology, 2009